To fully characterize cellular function and how it pertains to patient outcomes such as anti-tumor response or disease progression, functional proteomics is needed. Functional single-cell proteomics enable accelerated predictive insights into translational research and the development of novel immune therapies. With IsoPlexis’ ultra-small sample volume bulk secretomics, researchers can gain deep in vivo insights that were previously unattainable with traditional bulk assays.
IsoPlexis’ single-cell and highly multiplexed bulk secretomics provide sensitive immune profiling for a range of diseases, from infectious disease to cancer. Here, we will highlight recent studies in which IsoPlexis’ immune profiling delivered key omic insights that have the potential to accelerate curative medicines.
Sponsored by:
